Document Type : Original Article


Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran


Background: Now that the majority of the population has been immunized with two-dose vaccines, debates over the third booster dose have been raised. We studied the viewpoint of cases with multiple sclerosis (MS) on this matter.
Methods: In a cross-sectional study, a google form containing questions about participants’ characteristics, the history of coronavirus disease 2019 (COVID-19) infection and vaccination, and opinions on the third dose was designed.
Results: Of 1067 responders, only 16 (1.5%) were not vaccinated at all. The most used vaccine type was Sinopharm BBIBP COVID-19 vaccine (BBIBP-CorV) (n = 1002, 93.9%). Generally, 58 (5.4%) cases were hospitalized due to COVID-19. Of those with full vaccination, 134 (13.3%) got COVID-19 infection after the second dose. Only 13 participants (1%) did not agree with the third dose, while 564 (53.0%) believed that a booster dose was needed. Of all, 488 (45.7%) declared that they did not have a final idea and would follow the instructions by the experts. A significant association was found between not receiving the first two doses and not believing in the third dose (P = 0.001). 692 patients declared their reasoning for the importance of the third dose. All the cases who thought the administered vaccine was not efficient enough had received Sinopharm BBIBP-CorV. Those who got infected after full vaccination were more uncertain about the efficacy of the vaccine [odds ratio (OR): 2.6, 95% confidence interval (CI): 1.6-4.2].
Conclusion: It seems that the majority of the Iranian patients with MS expect the authorities to administer a third booster dose, especially if scientifically validated.


  1. Bensouna I, Caudwell V, Kubab S, Acquaviva S, Pardon A, Vittoz N, et al. SARS-CoV-2 antibody response after a third dose of the BNT162b2 vaccine in patients receiving maintenance hemodialysis or peritoneal dialysis. Am J Kidney Dis 2022; 79(2): 185-92.
  2. Westhoff TH, Seibert FS, Anft M, Blazquez-Navarro A, Skrzypczyk S, Zgoura P, et al. A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse. Kidney Int 2021; 100(5): 1135-6.
  3. S. Food and Drug Administration. FDA News Release. Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals [Online]. [cited 2021 Aug 12]; Available from: URL:
  4. Ghadiri F, Sahraian MA, Saeedi R, Naser MA. Attitudes toward vaccination in patients with multiple sclerosis: A report from Iran. Mult Scler Relat Disord 2021; 53: 103045.
  5. Abbasi N, Ghadiri F, Moghadasi AN, Azimi A, Navardi S, Heidari H, et al. COVID-19 vaccine hesitancy in Iranian patients with multiple sclerosis. Mult Scler Relat Disord 2022; 60: 103723.
  6. Ehde DM, Roberts MK, Humbert AT, Herring TE, Alschuler KN. COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021. Mult Scler Relat Disord 2021; 54: 103163.
  7. Neely SR, Scacco JM. Receptiveness of American adults to COVID-19 vaccine boosters: A survey analysis. PEC Innov 2022; 1: 100019.
  8. Jantzen R, Maltais M, Broet P. Socio-demographic factors associated with COVID-19 vaccine hesitancy among middle-aged adults during the Quebec's vaccination campaign. Front Public Health 2022; 10: 756037.
  9. Jha SS, Paul B, Das R, Chattopadhyay B, Lahiri A. Contributing factors of willingness and hesitancy regarding acceptance of COVID-19 vaccine in primary care settings: A qualitative study in an eastern state of India. J Educ Health Promot 2022; 11: 53.
  10. Xiang XM, Hollen C, Yang Q, Brumbach BH, Spain RI, Wooliscroft L. COVID-19 vaccination willingness among people with multiple sclerosis. Mult Scler J Exp Transl Clin 2021; 7(2): 20552173211017159.
  11. Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis 2021; 111: 219-26.
  12. Zhou Y, Wang Y, Li Z. Intention to get vaccinated against COVID-19 among nursing students: A cross-sectional survey. Nurse Educ Today 2021; 107: 105152.
  13. Teherani M, Banskota S, Camacho-Gonzalez A, Smith AGC, Anderson EJ, Kao CM, et al. Intent to vaccinate SARS-CoV-2 infected children in US households: A survey. vaccines (Basel) 2021; 9(9): 1049.
  14. Mousa M, Albreiki M, Alshehhi F, AlShamsi S, Marzouqi NA, Alawadi T, et al. Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the United Arab Emirates. J Travel Med 2022; 29(6): taac036
  15. Boshra MS, Hussein RRS, Mohsen M, Elberry AA, Altyar AE, Tammam M, et al. A battle against COVID-19: Vaccine hesitancy and awareness with a comparative study between Sinopharm and AstraZeneca. Vaccines (Basel) 2022; 10(2): 292.
  16. Khan WH, Hashmi Z, Goel A, Ahmad R, Gupta K, Khan N, et al. COVID-19 pandemic and vaccines update on challenges and resolutions. Front Cell Infect Microbiol 2021; 11: 690621.